Effects of a Probiotic on Oral Microbiota and Glycemic Control in Type 2 Diabetics; A Randomized Clinical Trial

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 10, 2015

Primary Completion Date

May 18, 2017

Study Completion Date

March 14, 2018

Conditions
Diabetes Mellitus,Type 2Periodontitis
Interventions
DIETARY_SUPPLEMENT

Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients

"The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse."

All Listed Sponsors
lead

Istanbul University

OTHER

NCT04913909 - Effects of a Probiotic on Oral Microbiota and Glycemic Control in Type 2 Diabetics; A Randomized Clinical Trial | Biotech Hunter | Biotech Hunter